Advances and Controversies in Adult ICU Sedation, Part 1: An Overview of the Importance of Sedation and Agitation and Subjective Assessment Tools for Patient Evaluation

2001 ◽  
Vol 36 (12) ◽  
pp. 1266-1278
Author(s):  
Gilles L. Fraser ◽  
Richard Riker
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
Critically Ill ◽  
Subjective Assessment ◽  
Assessment Tools ◽  
Critically Ill Patient ◽  
Patient Evaluation ◽  
Icu Patients ◽  
Icu Sedation ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient—an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at [email protected] .

Advances and Controversies in Adult ICU Sedation, Part 3: Evolving Pharmacological Treatment Issues

2002 ◽  
Vol 37 (4) ◽  
pp. 362-368 ◽  
Author(s):  
Gilles L. Fraser ◽  
Richard Riker
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
Critically Ill ◽  
Pharmacological Treatment ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Icu Patients ◽  
Recent Advances ◽  
Icu Sedation ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient—an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes.

Behavioral Effects of ICU Medications

2005 ◽  
Vol 40 (5) ◽  
pp. 387-392
Author(s):  
Gil Fraser ◽  
Richard R. Riker
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
Critically Ill ◽  
Economic Outcomes ◽  
Behavioral Effects ◽  
Critically Ill Patient ◽  
Icu Patients ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy for adult ICU patients (including evolving and controversial data) will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at [email protected] .

Early Treatment with Fluconazole in Adult ICU Patients at High Risk for Severe Candidiasis

2002 ◽  
Vol 37 (9) ◽  
pp. 928-935 ◽  
Author(s):  
Jason A. Yahwak ◽  
Gilles L. Fraser
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
High Risk ◽  
Critically Ill ◽  
Early Treatment ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Icu Patients ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient–an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes.

Important Changes in the ACLS 2000 Guidelines for the Management of Cardiac Arrest

2002 ◽  
Vol 37 (5) ◽  
pp. 469-473 ◽  
Author(s):  
Gilles L. Fraser ◽  
Sandra P. Bagwell
Keyword(s):  
Health Care ◽  
Cardiac Arrest ◽  
Drug Therapy ◽  
Critically Ill ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Icu Patients ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient—an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes.

Pharmacotherapy for Alcohol Withdrawal

2003 ◽  
Vol 38 (5) ◽  
pp. 420-425 ◽  
Author(s):  
Brian M. Hodges
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
Critically Ill ◽  
Alcohol Withdrawal ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Icu Patients ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy for adult ICU patients (including evolving and controversial data) will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at [email protected] .

Monitoring Low Molecular Weight Heparins with antiXa Activity: House of Cards or Firm Foundation?

2003 ◽  
Vol 38 (3) ◽  
pp. 202-211 ◽  
Author(s):  
Gilles L. Fraser ◽  
Joe P. Mckenna
Keyword(s):  
Health Care ◽  
Molecular Weight ◽  
Drug Therapy ◽  
Critically Ill ◽  
Critically Ill Patient ◽  
Low Molecular Weight ◽  
Low Molecular Weight Heparins ◽  
Icu Patients ◽  
House Of Cards ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes.

The Uncertain Risk of Single-Dose Etomidate in the Critically III

2005 ◽  
Vol 40 (8) ◽  
pp. 658-661 ◽  
Author(s):  
Gilles L. Fraser ◽  
Richard R. Riker
Keyword(s):  
Health Care ◽  
Single Dose ◽  
Drug Therapy ◽  
Critically Ill ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Icu Patients ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy for adult ICU patients (including evolving and controversial data) will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at [email protected] .

Vasopressin for Vasodilatory Shock

2002 ◽  
Vol 37 (11) ◽  
pp. 1149-1157 ◽  
Author(s):  
Brian M. Hodges ◽  
Gilles Fraser
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
Critically Ill ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Vasodilatory Shock ◽  
Icu Patients ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient–an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at [email protected] .

Corticosteroids in ARDS: The Never-Ending Story

2007 ◽  
Vol 42 (8) ◽  
pp. 691-701 ◽  
Author(s):  
Zachariah Thomas ◽  
Katarzyna Kimborowicz
Keyword(s):  
Health Care ◽  
Intensive Care Unit ◽  
Intensive Care ◽  
Drug Therapy ◽  
Critically Ill ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Adult Intensive Care Unit ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy (including evolving and controversial data) for adult intensive-care-unit patients will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes.

scholarly journals The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID-19 patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Josef D. Järhult ◽  
Michael Hultström ◽  
Anders Bergqvist ◽  
Robert Frithiof ◽  
Miklos Lipcsey
Keyword(s):  
Organ Failure ◽  
Critically Ill ◽  
Independent Predictor ◽  
Corticosteroid Treatment ◽  
Blood Stream ◽  
Common Finding ◽  
Icu Patients ◽  
Extra Pulmonary ◽  
The Impact ◽  
Swedish Cohort

AbstractThe spread of virus via the blood stream has been suggested to contribute to extra-pulmonary organ failure in Coronavirus disease 2019 (COVID-19). We assessed SARS-CoV-2 RNAemia (RNAemia) and the association between RNAemia and inflammation, organ failure and mortality in critically ill COVID-19 patients. We included all patients with PCR verified COVID-19 and consent admitted to ICU. SARS-CoV-2 RNA copies above 1000/ml measured by PCR in plasma was defined as RNAemia and used as surrogate for viremia. In this cohort of 92 patients 59 (64%) were invasively ventilated. RNAemia was found in 31 patients (34%). Hypertension and corticosteroid treatment was more common in patients with RNAemia. Extra-pulmonary organ failure biomarkers and the extent of organ failure were similar in patients with and without RNAemia, but the former group had more renal replacement therapy and higher mortality (26 vs 16%; 35 vs 16%, respectively, p = 0.04). RNAemia was not an independent predictor of death at 30 days after adjustment for age. SARS-CoV2 RNA copies in plasma is a common finding in ICU patients with COVID-19. Although viremia was not associated with extra pulmonary organ failure it was more common in patients who did not survive to 30 days after ICU admission.Trial registration: ClinicalTrials NCT04316884.

Sign in / Sign up

Export Citation Format

Share Document